Darmstadt, Germany, February 21, 2012 - Merck announced today that it is selling its electrolytes business for high-performance batteries to BASF. The companies have agreed not to disclose the financial details of the transaction.

• More IR News

Darmstadt, Germany, February 3, 2012 – Merck KGaA today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug. TH-302 is currently being investigated in a global Phase III clinical trial in patients with soft tissue sarcoma, a randomized Phase II trial in patients with advanced pancreatic cancer from which top-line results are expected in February, as well as additional clinical studies in other solid tumors and hematological malignancies.

• More IR News

“The Merck Group produced solid third-quarter revenue growth in a difficult environment, driven mainly by good performances from the Merck Serono and Merck Millipore divisions. Net profit rose by 8% on higher revenues and as one-time costs from last year were not repeated, leaving us well positioned as we head into the end of the year,” said Dr. Karl-Ludwig Kley, Chairman of the Executive Board of Merck KGaA. “We are making progress in driving our change agenda forward and we will provide important updates on this endeavor in the first half of 2012.”

• Read the HalfyYear Financial Report online
• Business Results
• Press Release